Professor Chen Minshan: IMbrave150 research re-weight results, China sub-group OS breakthrough 24 months!

With the development of medical science and technology, the field of liver cancer treatment is in bloom.
, especially immuno combination therapy, has brought new choices and hopes for patients with advanced liver cancer.
in the newly published IMbrave150 study, atili-pearl monoantigen (the "T-A" scheme) reduced the risk of death by 34%, the medium total survival (OS) reached 19.2 months, and the middle OS of Chinese sub-group patients exceeded 24.0 months! Progress-free lifetime (PFS), objective efficiency (ORR), etc. are consistent with earlier analysis results, and their safety is consistent with previously known safety characteristics of individual drug use, and no new safety signals have been detected.
to this, the doctor had the honor to interview Professor Chen Minshan, Director of Liver Surgery at Sun Yat-sen University Cancer Prevention and Control Center and Director of the Institute of Liver Cancer research at Sun Yat-sen University, to introduce the advantages of immuno combination therapy in liver cancer treatment and the new direction of future exploration.
Professor Chen Minshan Professor Sun Yat-sen University Cancer Prevention and Control Center, Director of Liver Surgery, Director of the Liver Cancer Research Institute of Sun Yat-sen University, Chairman of the Liver Cancer Professional Committee of the Chinese Physicians Association, Vice Chairman of the Liver Cancer Professional Committee of the Chinese Physicians Association, Vice Chairman of the Working Committee of the Chinese Society of Clinical Oncology (CSCO) Liver Cancer, Former Chairman of the Liver Cancer Branch of the Guangdong Medical Association, Former Chairman of the Liver Cancer Professional Committee of the Guangdong Anti-Cancer Association Honorary Chairman of the Chinese Medical Association Branch of the Liver Surgery Group member of the Chinese Medical Association Hepatology Credit Committee of the Chinese Medical Association Oncology Credit Committee of the Liver Cancer Group member asked: IMbrave150 research recently released the total survival data is exciting, but also once again confirmed the strength of the "T-A" joint treatment program.
would you like to talk about the treatment benefits of the "T-A" program in advanced liver cancer? Professor Chen Minshan: In recent years, with the development of medicine, immunotherapy has become a hot spot in the field of cancer treatment.
, especially immuno combination therapy, has given more options to the treatment of patients with hepatocellular carcinoma (HCC).
as a pioneer and explorer in the era of immunotherapy, the "T-A" programme is the first immune co-programme in the world to be shown to be superior to Solafini in the treatment of HCC.
In the newly published IMbrave150 study, we were pleased to see that the mid-level OS in the global population reached 19.2 months after patients with advanced HCC received the "T-A" program, and that the mid-OS in the Chinese sub-group exceeded 24 months, suggesting that the "T-A" program is more effective for Chinese patients.
same time, the study also found that the objective efficiency (ORR) of the "T-A" scheme was up to 30%, and that the side effects of the "T-A" scheme were significantly reduced and the patient's tolerance was better compared to Solafini.
addition, the "T-A" program is also very simple to use drugs, every 3 weeks intravenously can be, without daily medication, patient compliance is better.
, the findings are a landmark change and an encouraging breakthrough in the treatment of liver cancer.
in the future, we also expect more clinical data to further confirm the benefits of the "T-A" programme and to include these eye-catching findings in the guidelines to better guide primary hospitals in their care.
: Based on the positive results of the IMbrave150 global and Chinese groups, as a hepatosurgery specialist, based on your clinical experience, do you think there are any new directions in the future that the "T-A" programme will be worth exploring further in the future? Professor Chen Minshan: In the field of liver cancer treatment, there are many ways to explore the future.
, for the post-surgery complementary treatment of liver cancer, there is currently a global study under way, and Sun Yat-sen University Affiliated Oncology Hospital is also involved in this global study, I am fortunate to be one of China's major PI.
because liver cancer patients are prone to recurrence after surgery, we try to use the "T-A" program to further treat patients and observe their benefits.
hopes that clinical trials will identify the best adaptations for the drug, screen patients who are better suited to the treatment, and how to work together to achieve the best results, which will require a constant accumulation of clinical experience, and we look forward to clinical outcomes.
In addition, multidisciplinary treatment is also of great significance for liver cancer treatment: First, because of the limitations of a single treatment method (e.g. simple surgery, simple interventional treatment, etc.), it is not possible to obtain the desired therapeutic effect, so multidisciplinary comprehensive treatment is needed.
, the single treatment used by patients may not be the most appropriate choice, and therefore often does not achieve the best results.
, multidisciplinary treatment not only helps to improve patient efficacy, but also reduces the cost of treatment.
more treatment options, it is also easier to find the best solution, which avoids a single approach to repeated treatment, thereby benefiting patients more.
in the newly released "China's Multidisciplinary Integrated Therapist Consensus on Liver Cancer", the "T-A" program is also featured, which proves the status and role of the therapy in multidisciplinary treatment.
, when the tumor is in local lesions, local treatment methods such as surgery, intervention, ablation and so on can be used.
when the lesions of the authorities metasnthesized, spread and produced systemic lesions, systemic treatment and "local plus whole body" combined treatment methods can be used.
, especially the use of the "T-A" program, greatly enriches the "local plus whole body" treatment model, giving patients the opportunity to achieve more accurate results.
this article is authorized to reproduce